Chris Calcaterra

“And we were excited about getting approval for iPrime as early as we did, and we are planning for a Q2 launch. In terms of how that will be used, that will be up to the physician in terms of how he or she wants to utilize it, when he or she wants to utilize it.”

“And we're pleased with what we've been able to accomplish, and that is certainly a result of all the different initiatives that we put into place mostly around early detection of corneal conditions and referral patterns of getting these patients into iLink customers, good integration of the Avedro and Glaukos team and…”

“So that’s an in-process R&D charge associated with the upfront amount that we paid to Intratus associated with the expansion of the license into presbyopia, as Tom mentioned.”

“We're excited about having yet another product in our bag. We see this as potentially as a stand-alone as well as complementary to our trabecular bypass products.”

“I would say that going back to a year ago, there was a lot of trying and trialing going on. And since then, there's less of that. Speaking of Ivantis, it's been out there for two years.”